Jiang Jing, Liu Ning, Yang Yuanhong, Zhang Yafeng
Anorectal Department, Suining Central Hospital Suining 629000, Sichuan, China.
Am J Transl Res. 2024 Dec 15;16(12):7491-7500. doi: 10.62347/TJRK1442. eCollection 2024.
This study focuses on analyzing the efficacy of lactulose oral solution combined with Macrogol 4000 Powder in the treatment of functional constipation (FC).
A total of 125 FC patients were selected, with 60 cases in a control group, who were treated with lactulose oral solution alone, and 65 cases in a research group, who were treated with lactulose oral solution combined with Macrogol 4000 Powder. The two groups were analyzed and compared in terms of efficacy, symptom recovery, Bristol Stool Form Scale (BSFS) and Wexner Constipation Scale (WCS) scores, adverse effects, serum indices, and Patient Assessment of Constipation Quality of Life (PAC-QOL). Univariate and multivariate analyses were performed to identify risk factors affecting the efficacy.
The total response rate of treatment in the research group was higher than that in the control group, and the symptom recovery was significantly better in the research group. In addition, the research group showed markedly elevated BSFS scores and reduced WCS scores after treatment as compared to the control group. Furthermore, significantly better improvements in various serum indices were determined in the research group. There was no remarkable difference in the incidence of total adverse reactions between groups. Finally, the course of disease, hypertension, diabetes, hyperlipidemia, and therapeutic method were identified to be factors affecting treatment efficacy in patients with FC.
The efficacy therapeutic of lactulose oral solution combined with Macrogol 4000 Powder in the treatment of FC is promising.
本研究聚焦于分析乳果糖口服溶液联合聚乙二醇4000散治疗功能性便秘(FC)的疗效。
共选取125例FC患者,其中对照组60例,仅接受乳果糖口服溶液治疗;研究组65例,接受乳果糖口服溶液联合聚乙二醇4000散治疗。对两组患者的疗效、症状恢复情况、布里斯托大便分类法(BSFS)和韦克斯纳便秘量表(WCS)评分、不良反应、血清指标以及便秘生活质量患者评估(PAC-QOL)进行分析和比较。进行单因素和多因素分析以确定影响疗效的危险因素。
研究组的总治疗有效率高于对照组,且研究组的症状恢复情况明显更好。此外,与对照组相比,研究组治疗后BSFS评分显著升高,WCS评分降低。而且,研究组各项血清指标的改善情况明显更好。两组间总不良反应发生率无显著差异。最后,确定病程、高血压、糖尿病、高脂血症和治疗方法是影响FC患者治疗疗效的因素。
乳果糖口服溶液联合聚乙二醇4000散治疗FC的疗效前景良好。